A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.

被引：6
|
作者：
El-Rayes, Bassel F.
Shanda, Safi
Starodub, Alexander
O'Neil, Bert H.
Hanna, Wahid Tewfik
Shaib, Walid Labib
Oh, Cindy
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Indiana Univ, Hlth Goshen Ctr Canc Care, Bloomington, IN 47405 USA
[4] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Univ Tennessee, Med Ctr, Knoxville, TN USA
[6] Boston Biomed Inc, Boston, MA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supp1.4128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4128
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H. Ko
    Thach-Giao Truong
    Emily Kantoff
    Kimberly A. Jones
    Elizabeth Dito
    Anna Ong
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 875 - 881
  • [32] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
  • [33] Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
    Pijnappel, E. N.
    Klaassen, R.
    van der Lee, K. S.
    Pleunis-van Empel, M.
    Richel, D.
    Legdeur, M.
    Nederveen, A.
    van Laarhoven, H. W. M.
    Wilmink, H. W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
    Dotan, Efrat
    Cardin, Dana B.
    Lenz, Heinz-Josef
    Messersmith, Wells
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Astsaturov, Igor
    Kapoun, Ann M.
    Brachmann, Rainer K.
    Uttamsingh, Shailaja
    Stagg, Robert J.
    Weekes, Colin
    CLINICAL CANCER RESEARCH, 2020, 26 (20) : 5348 - 5357
  • [35] Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
    Dotan, Efrat
    Cardin, Dana Backlund
    Lenz, Heinz-Josef
    Messersmith, Wells A.
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Kapoun, Ann M.
    Brachmann, Rainer Karl
    Uttamsingh, Shailaja
    Weekes, Colin D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [36] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Bertels, Barbara
    Wapinsky, Georgine
    Almhanna, Khaldoun
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2019, 37 : 797 - 797
  • [38] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Phase 1b study of gemcitabine, nab-paclitaxel, and ficlatuzumab in patients with advanced pancreatic cancer.
    Perez, Kimberly
    Rubinson, Douglas Adam
    Cleary, James M.
    Meyerhardt, Jeffrey A.
    Patel, Anuj K.
    Abrams, Thomas Adam
    Rahma, Osama E.
    Raghavan, Srivatsan
    Aguirre, Andrew
    Needle, Michael N.
    Das, Koushik
    Pitarresi, Jason
    Bakir, Basil
    Rustgi, Anil K.
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Prognostic factors for GEM plus nab-PTX combination therapy in elderly patients with pancreatic cancer.
    Watabe, Kazuki
    Ohno, Izumi
    Sakai, Miho
    Takahashi, Tomoya
    Yamada, Nana
    Tohyama, Shodai
    Sekine, Yu
    Sugihara, Jihei
    Ohuchi, Mayu
    Nagashima, Hiroki
    Takahashi, Koji
    Okitsu, Kohichiro
    Kan, Motoyasu
    Ohyama, Hiroshi
    Ohtsuka, Masayuki
    Kato, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 678 - 678
12345